Arthneeti
All Q2 FY26 results →
C

Cipla Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Cipla Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,325
Market cap₹1.1L Cr
P/E29.9
Updated16 Oct 2026
Read4 min read

The short version

Cipla aims to achieve approximately $1 billion in U.S. Cipla delivered highest-ever quarterly revenue of INR 7,589 crores in Q2 FY26, growing 8% YoY.

From Cipla Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

  • Cipla aims to achieve approximately $1 billion in U.S. sales next year, depending on the timing of product launches and approvals.
  • The U.S. generic base business, excluding Revlimid, is expected to continue growing in Q3 FY26 compared to Q2.
  • Launches of four major respiratory assets and three peptide assets, including liraglutide, by calendar year 2026 are expected to drive growth.
  • Cipla plans to expand its biosimilars portfolio, including internal developments and partnerships, targeting 2-3 new products over the next 2-3 years.
  • In the domestic market, Cipla expects to outperform market growth in both branded generic and trade generics segments with a focus on chronic therapies and lifestyle-related conditions (e.g., diabetes, obesity).
  • Africa and EMEU markets show positive growth with continued market penetration and margin expansion.

2 more points from Cipla Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Cipla Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Cipla is undertaking capacity expansion at its Fall River facility, particularly for respiratory products.
  • The company mentioned that U.S. manufacturing costs are higher than in India due to labor expenses, despite similar capex levels.
  • The respiratory manufacturing plants are fairly automated to manage costs.
  • Cipla is pursuing multiple independent filings for respiratory products like Redihaler and QVAR.
  • Additional R&D investments are being made, with accelerated filings in complex generics, respiratory, oligos, and peptides.
  • Total R&D spend is trending higher this year, about 0.5% of revenue higher than planned, to capitalize on new opportunities.

2 more points from Cipla Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Cipla Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript does not explicitly mention Cipla Limited's current or expected order book or pending orders. However, some relevant insights related to demand and supply are as follows: - Cipla is the only partner to shape the market for tirzepatide with nationwide distribution, implying strong expected demand and supply coverage. - The company has accelerated product filings and increased R&D spend, indicating an expanding pipeline to address growing market opportunities. - For certain products like Abraxane and nanopaclitaxel, market share is currently low but expected to grow, indicating ongoing order buildup.

2 more points from Cipla Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Cipla Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹6.5K Cr, net profit ₹543 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Cipla's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Cipla Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Cipla Ltd Q2 FY26 results?

Cipla aims to achieve approximately $1 billion in U.S. Cipla delivered highest-ever quarterly revenue of INR 7,589 crores in Q2 FY26, growing 8% YoY.

What is Cipla Ltd share price analysis?

Cipla Ltd currently shows a neutral. The stock trades at a P/E of 29.9 with a market cap of ₹107,051 Cr. Investors should review the full earnings analysis for detailed insights.

Is Cipla Ltd planning capital expenditure?

Cipla is undertaking capacity expansion at its Fall River facility, particularly for respiratory products.

Keep Cipla Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.